SCHEMBL4202602

SCHEMBL4202602

O=c1c2cccnc2nc(-c2ccc(F)cc2)n1NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
TACR1 P25103 2/20 0.42
KAT2B Q92831 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
EP300 Q09472 1/20 0.42
CREBBP Q92793 1/20 0.42
KAT2A Q92830 1/20 0.42
HTR1A P08908 2/20 0.42
DRD2 P14416 2/20 0.42
HTR7 P34969 2/20 0.42
HTR6 P50406 2/20 0.42
IDO1 P14902 1/20 0.40
SUCNR1 Q9BXA5 2/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
ABCG2 Q9UNQ0 2/20 0.38
VNN1 O95497 1/20 0.38
TRPV1 Q8NER1 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4202613 0.88 SMN1; SMN2 (0.48) SMN1; SMN2KAT2BEP300CREBBPKAT2A
SCHEMBL4199192 0.88 SMN1; SMN2 (0.48) SMN1; SMN2KAT2BNPSR1IDO1LMNA
SCHEMBL4237693 0.85 SMN1; SMN2 (0.64) SMN1; SMN2KDM4ENPSR1LMNAPOLB
SCHEMBL4200494 0.84 SMN1; SMN2 (0.48) SMN1; SMN2KAT2BNPSR1IDO1LMNA
SCHEMBL4233689 0.79 SMN1; SMN2 (0.48) SMN1; SMN2NPSR1LMNAPOLBCYP1A2
SCHEMBL4188985 0.77 MAPT (0.46) SMN1; SMN2NPSR1IDO1LMNAPOLB
SCHEMBL4233285 0.76 MAPT (0.55) SMN1; SMN2KDM4ENPSR1LMNAPOLB
SCHEMBL4233701 0.76 SMN1; SMN2 (0.63) SMN1; SMN2TACR1KDM4ENPSR1LMNA
SCHEMBL4233257 0.76 ALDH1A1 (0.53) SMN1; SMN2KDM4ENPSR1LMNAPOLB
SCHEMBL4241958 0.76 MAPT (0.49) SMN1; SMN2NPSR1LMNAPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-04-23 US disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed
WO-2009026241-A1 HETEROCYCLIC MODULATORS OF TGR5 KALYPSYS, INC. (US) 2009-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090105124-A1 HETEROCYCLIC MODULATORS OF TGR5 GPBAR1, GPR119, GRK5 SMN1; SMN2 3183/4885TACR1 440/4885KAT2B 3006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.